Standard of Care Payment Overlap
Pharmaceutical and biotech clinical trials in the United States assume $1.1 billion in patient treatment costs that would normally be covered by commercial and public third party payers. These medical procedures are often a part of the treatment third party payers are required to provide their patients. Many pharmaceutical and biotech companies routinely include standard of care payment considerations in their clinical grant payment agreements with sites conducting oncology studies. However, this standard of care payment practice is usually not widely followed in other therapeutic areas, despite its broad acceptance in oncology. An analyses of US Phase I and III clinical studies, outside of oncology, shows that 22% of clinical trial procedures paid for by pharmaceutical companies would be covered by public and commercial third party payers as part of their standard of care treatment for these patients. Drawing upon data from GrantPlan®, the industry’s largest current database of clinical grants, and over 1 billion patient claims records, TTC and Trialytics determined that commercially funded Phase II-IVclinical trials are far more expensive than they need to be.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
